Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Atea Pharmaceuticals (AVIR) Cash from Investing Activities (2020 - 2022)

Atea Pharmaceuticals has reported Cash from Investing Activities over the past 2 years, most recently at $33.5 million for Q4 2022.

Quarterly results put Cash from Investing Activities at $33.5 million for Q4 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was -$455.4 million (changed N/A YoY), and the annual figure for FY2025 was $188.8 million, up 236.5%.
Cash from Investing Activities for Q4 2022 was $33.5 million at Atea Pharmaceuticals, up from -$487.0 million in the prior quarter.
Over the last five years, Cash from Investing Activities for AVIR hit a ceiling of $33.5 million in Q4 2022 and a floor of -$487.0 million in Q3 2022.